An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion.

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion.

Publication date: Mar 15, 2019

This article discusses the opinions of the multiple sclerosis (MS) experts in the Gulf region on the use of high-efficacy disease-modifying drugs (DMDs; natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab) in clinical practice. The experts reviewed the current literature including pivotal clinical trials and meta-analyses for high-efficacy DMDs, supplemented by the expert opinions on the usage of these DMDs in clinical practice. Several criteria were discussed by the panel based on different efficacy, safety, and convenience attributes. The panel concluded that all the DMDs available for the treatment of MS have benefits and risks, which should be considered while discussing the treatment plan with the patient. It is important to have a personalized approach based on the risk-benefit assessment for each case. Common considerations while choosing treatments include effectiveness, side effects/safety, and convenience/route of administration.Funding: Merck Serono Middle East FZ LTD.

Alroughani, R., Inshasi, J.S., Deleu, D., Al-Hashel, J., Shakra, M., Elalamy, O.R., Shatila, A.O., Al-Asmi, A., Sharoqi, Al, Canibano, B.G., and Boshra, A. An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion. 17524. 2019 Neurol Ther.

Concepts Keywords
Alemtuzumab Natalizumab
Cladribine Fingolimod
Clinical Trials Ocrelizumab
Common Multiple sclerosis
Fingolimod Purines
Middle East Organochlorides
Multiple Sclerosis Cladribine
Natalizumab Immunology
Tablets Medical specialties
Immunosuppressants
Monoclonal antibodies
Drugs

Semantics

Type Source Name
drug DRUGBANK Ocrelizumab
drug DRUGBANK Cladribine
drug DRUGBANK Alemtuzumab
drug DRUGBANK Fingolimod
drug DRUGBANK Natalizumab
disease DOID Multiple Sclerosis
disease MESH Multiple Sclerosis

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *